Article Sidebar

pdf
Date Published: 15/04/2024
Abstract Views: 54
Views pdf: 45
DOI: https://doi.org/10.51298/vmj.v537i2.9240
Issue
Vol. 537 No. 2 (2024)
Section
Các bài báo
How to Cite
Đỗ, A. T., & Nguyễn, Đình L. (2024). EFFECT OF ABIRATERONE ACETATE DOSE ON THE RESULTS OF TREATMENT WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS. Vietnam Medical Journal, 537(2). https://doi.org/10.51298/vmj.v537i2.9240

EFFECT OF ABIRATERONE ACETATE DOSE ON THE RESULTS OF TREATMENT WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

Anh Tú Đỗ, Đình Lợi Nguyễn

Main Article Content

Abstract

Objective: Evaluating the effect of Abiraterone acetate dose on treatment outcomes in patients with castration-resistant metastatic prostate cancer. Patients and methods: A cross-sectional descriptive study on 65 patients with metastatic castration-resistant prostate cancer in Vietnam National Cancer Hospital from January 2014 through May 2023. Kaplan-Meier curves were used to estimate the time to treatment failure (TTF). Results: Abiraterone acetate doses of 1000mg/day and 500mg/day were prescribed for most patients (47,7% and 38,5%). The median time to treatment failure was 15.0 months (95% CI: 11,1-18,9). The group of patients starting treatment with Abiraterone acetate 1000mg/day had a higher median TTF than those starting treatment with 250-750mg/day (17,0 months vs 11,0 months, p=0.112). The median TTF of the 250-500mg maintenance treatment group was significantly higher than that of the 1000mg/day maintenance treatment group (19,8 months vs 8,7 months, p=0.007). Conclusion: In patients with PSA reduced by over 90% compared to before treatment, maintenance treatment of Abiraterone acetate 250-500mg/day gives good results.

Article Details

Keywords

Prostate cancer, metastatic castration-resistant prostate cancer, the treatment dose of Abiraterone acetate

References

1. Cancer today. , accessed: 24/07/2023.
2. Ryan C.J., Smith M.R., Fizazi K. và cộng sự. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16(2), 152–160.
3. Scher H.I., Morris M.J., Stadler W.M. và cộng sự. (2016). Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol, 34(12), 1402–1418.
4. Boegemann M., Khaksar S., Bera G. và cộng sự. (2019). Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC Cancer, 19(1), 60.
5. Pilon D., Behl A.S., Ellis L.A. và cộng sự. (2017). Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. JMCP, 23(2), 225–235.
6. M A, A B, M G, J J, R DV, N T. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer chemotherapy and pharmacology. 2012;69(6). doi:10.1007/s00280-012-1865-3
7. Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ. Low-Dose Abiraterone With Food: Rebutting an Editorial. JCO. 2018; 36(30): 3060-3061